Search clinical trials for: Placebo naltrexone

Total 54070 results

University of California, Los Angeles
National Institute of Mental Health (NIMH)

Enrolling by invitation

Opioids and Social Support Enhanced Extinction Effects (SSO)

Fear

United States
VA Office of Research and Development

Completed

Low Dose Naltrexone for Chronic Pain From Arthritis (LDN-VA)

Arthritis, Rheumatoid | Osteoarthritis | Arthritis, Psoriatic

United States
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); American...

Completed

Naltrexone and Hypoglycemia in Type 1 Diabetes (Naltrexone)

Type 1 Diabetes | Hypoglycemia Unawareness

United States
Medical University of South Carolina

Completed

Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

Alcohol Dependence

United States
University of Minnesota

Withdrawn

Naltrexone in the Treatment of Pyromania

Pyromania

United States
Central Institute of Mental Health, Mannheim
University of Freiburg

Completed

Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

Borderline Personality Disorder | Dissociation

Germany
NYU Langone Health
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Completed

Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry (XOR)

Opioid-Related Disorders | Heroin Dependence

United States
Mundipharma (China) Pharmaceutical Co. Ltd

Unknown

Buprenorphine Transdermal Patches Pharmacokinetic Study

Chronic Pain

China
Pfizer

Terminated

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Moderate-severe Pain

United States
Pfizer

Terminated

Conversion to Embeda With Rescue Trial (ConvERT)

Pain | Chronic Disease

United States
University of Minnesota

Withdrawn

Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone

Dermatitis | Pruritus | Atopic Dermatitis

United States
Western Michigan University School of Medicine
Kalamazoo Community Foundation

Withdrawn

Evaluation of Naltrexone as a Treatment for Self-injurious Behavior (NTX-SIB)

Self Mutilation | Self-injurious Behavior

United States
Brigham and Women's Hospital
VA Boston Healthcare System

Withdrawn

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

Arthritis, Rheumatoid | Osteoarthritis | Arthritis, Psoriatic

United States
University of Minnesota

Completed

Double-Blind Naltrexone in Kleptomania

Kleptomania

United States
Technische Universität Dresden

Completed

Validation of a Test System for Development of Medications for Alcoholism (TEMANX)

Alcoholism

Germany
UConn Health
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Targeted Naltrexone for Problem Drinkers

Alcohol Drinking | Alcohol Dependence | Alcoholism

United States
Copenhagen University Hospital at Herlev

Withdrawn

Palliative Treatment of Ulcerated Cutaneous Metastases: Trial Between Electrochemotherapy and Radiotherapy

Ulcerated Cutaneous Metastases

Denmark
University of Minnesota

Withdrawn

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

Dermatitis | Pruritus | Atopic Dermatitis | Pruritus Chronic

United States
Stanford University
National Institute of Mental Health (NIMH)

Recruiting

Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2) (MKET2)

Obsessive-Compulsive Disorder

United States
Annette C. Toledano MD

Completed

Naltrexone and Clonidine Combination (ATNC05) in the Treatment of Chronic Back Pain

Lower Back Pain | Back Pain | Cervical Pain

United States
Medical University of South Carolina
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone

Alcohol Dependence

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)

Completed

Extended Release Naltrexone for Opioid-Dependent Youth

Drug Dependence

United States
Institute of Liver and Biliary Sciences, India

Completed

Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.

Liver Cirrhosis

India
Boston Medical Center
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin (UH3)

HIV Infections | Chronic Pain | Alcohol Use, Unspecified

Russian Federation
The Taub Group

Completed

The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression

Depression

United States
Ensysce Biosciences
PRA Health Sciences

Completed

Study of PF614 Compared to OxyContin® in Healthy Volunteers (SAD)

Healthy

United States
University of Vermont Medical Center
National Institute on Drug Abuse (NIDA)

Completed

Effective Treatment for Prescription Opioid Abuse

Prescription Opioid Dependence

United States
University of Pennsylvania

Not yet recruiting

Brain Mechanisms of Pharmacotherapy in Opioid Use Disorder

Opioid Dependence
Alza Corporation, DE, USA

Completed

A Study to Evaluate the Safety of D-TRANS Fentanyl With Naltrexone in Adult Patients With Chronic Pain and Who Are Opioid Tolerant

Chronic Pain
National Development and Research Institutes, Inc.
St. Luke's-Roosevelt Hospital Center

Unknown

Science-Based Treatment for Opioid-Dependent Adolescents

Opioid-Dependence Among Adolescents

United States
University of Arkansas
National Institute on Drug Abuse (NIDA)

Completed

Improving Treatment Outcomes for Prescription Opioid Dependence (GBN)

Drug Dependence

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Binge-Eating Disorder

United States
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Naltrexone for Antipsychotic-Induced Weight Gain (NTX)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Bipolar Disorder | Severe Major Depression With Psychotic Features

United States
Massachusetts General Hospital
Boston Clinical Trials (BCT)

Completed

Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence

Recurrence | Major Depressive Disorder | Depression, Unipolar | Relapse

United States
University of Pennsylvania
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

Alcohol Dependence | Alcoholism | Post-Traumatic Stress Disorder

United States
Minia University

Completed

The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer

Cornea Ulcer

Egypt
Pfizer

Completed

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

Chronic Noncancer Pain

United States
Pfizer

Completed

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Pain

United States
Friends Research Institute, Inc.

Recruiting

Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail

Opioid-use Disorder

United States
Purdue Pharma LP

Completed

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

ECG Effects

United States
University of California, San Francisco

Completed

Stress, Hormones, and Eating (SHE)

Food Addiction | How Opioid Tone Was Related to Self Reported | Drive to Eat Using a Measure of Food Addiction
Bausch Health Americas, Inc.
Pfizer

Completed

A a Single Dose Efficacy Study in Inducing Laxation in Advance Illness Patients

Advanced Illness Patients With Opioid Induced Constipation

United States
RWTH Aachen University

Terminated

Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System

Alcohol Addiction

Germany
Centre for Addiction and Mental Health

Terminated

Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers

Alcohol Dependence

Canada
Allodynic Therapeutics, LLC

Completed

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

Migraine With and Without Aura

United States
Sassani, Joseph S., MD, MHA

Completed

Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects

Dry Eye Disease

United States
H. Lundbeck A/S

Completed

Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge

Alcohol Dependence

United Kingdom
Pharnext S.C.A.
Worldwide Clinical Trials

Active, not recruiting

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PREMIER)

Charcot-Marie-Tooth Disease

United States, Spain, Belgium, Italy, Israel, Canada, Denmark, France, Germany
Shanghai Mental Health Center
University of Massachusetts, Worcester

Completed

Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia

Schizophrenia | Obese | Cigarette-smoking
University of California, Los Angeles
Alkermes, Inc.

Completed

Injectable Pharmacotherapy for Opioid Use Disorders (IPOD) (IPOD)

Opioid Use Disorders

United States

Search clinical trials for: Placebo naltrexone

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations